ONCOLife Issues
Featured Articles
Trending Articles
PADCEV–KEYTRUDA Combination Delivers Survival Gains in High-Risk Bladder Cancer
ONCOLife | 12 August 2025
FDA Grants Fast Track Designation to Birelentinib for Relapsed/Refractory CLL and SLL
FDA & EMA | 9 August 2025
Epcoritamab + R2 Achieves 95.7% ORR, Cuts Risk by 79% in R/R Follicular Lymphoma
ONCOLife | 8 August 2025
Novel Viral Immunotherapy SuperNova Gains FDA Fast Track Designation for Sarcoma
FDA & EMA | 4 August 2025
FDA Fast-Tracks Breyanzi as First CAR T Cell Therapy for Marginal Zone Lymphoma
FDA & EMA | 5 August 2025
FDA Approves Modeyso as First-Ever Therapy for Pediatric Brain Tumor, H3 K27M+ Glioma
FDA & EMA | 6 August 2025
2025 Pan-Mass Challenge Draws Thousands of Cyclists to Fuel Next Era of Cancer Research
ONCOLife | 3 August 2025
Targeting eIF2A to Halt Melanoma: Study Reveals Key Driver of Cancer Cell Migration
ONCOLife | 2 August 2025
Dr. Iris Kuss: ARANOTE Trial Results Signal a New Era in Prostate Cancer Treatment
ONCOLife | 1 August 2025
Global Data Warns of Secondary Cancers Linked to CAR-T Therapy, Urging Monitoring
ONCOLife | 31 July 2025
Promising Results: Jaypirca Outperforms Imbruvica in Landmark Phase 3 CLL/SLL Trial
Clinical Trials | 30 July 2025
EMA Grants Orphan Drug Designation to Nuvisertib for Rare Blood Cancer Myelofibrosis
FDA & EMA
30 July 2025
A Mitochondrial Makeover: Rewiring T Cells to Supercharge Cancer Immunotherapy
ONCOLife
29 July 2025
Imfinzi Receives FDA Priority Review as First Immunotherapy for Gastric and GEJ Cancers
FDA & EMA
28 July 2025
START and Advarra Unite to Streamline Early-Phase Oncology Trials with Speed
Digital Health
25 July 2025